The Long-Term Safety and Efficacy of Intrathecal Therapy Using Sufentanil in Chronic Intractable Non-Malignant Pain.
10.3344/kjp.2014.27.3.297
- Author:
Jose Jesus MONSIVAIS
1
;
Diane Burn MONSIVAIS
Author Information
1. Hand and Microsurgery Center of El Paso, Orthopedics and Rehabilitation, Texas Tech University Health Science Center (TTUHSC), Texas, USA. handmicro@msn.com
- Publication Type:Brief Communication
- Keywords:
implantable infusion pump;
intractable pain;
neuropathic pain;
sufentanil
- MeSH:
Arm;
Chronic Pain;
Drug-Related Side Effects and Adverse Reactions;
Granuloma;
Hand;
Humans;
Infusion Pumps, Implantable;
Mass Screening;
Neuralgia;
Pain Management;
Pain, Intractable;
Patient Selection;
Quality of Life;
Surveys and Questionnaires;
Shoulder;
Statistics as Topic;
Sufentanil*;
Visual Analog Scale
- From:The Korean Journal of Pain
2014;27(3):297-300
- CountryRepublic of Korea
- Language:English
-
Abstract:
This report describes the long term safety and efficacy of intrathecal therapy using Sufentanil for the management of chronic intractable neuropathic pain in 12 chronic pain patients. Standardized psychological screening was used to determine treatment suitability. Evaluation data included the Visual Analog Scale (VAS), Wong-Baker Faces Scale, Brief Pain Inventory (BPI), Disability of Arm, Shoulder, and Hand (DASH), McGill Quality of Life Questionnaire, and complications (granulomas, toxicity, withdrawal, or deaths). SPSS version 18 was used for data analysis. Pre- and post- treatment BPI measures and pain scale scores showed a statistically significant difference. There were no complications directly related to drug toxicity, nor drug withdrawals, granulomas, or deaths. Intrathecal therapy with Sufentanil therapy offers a good treatment alternative for those cases that have failed both surgery and standard pain treatment. Strict patient selection based on psychological screening, control of co-morbidities, a proper pain management may contribute to successful outcome.
